Using cancer drivers to trigger cell death in lymphoma
HIJACKING CANCER DRIVERS TO ACTIVATE PROAPOPTOTIC GENES IN DLBCL
This study is exploring a new way to help people with Diffuse Large B-Cell Lymphoma by using special molecules that can help cancer cells turn on their own self-destruct buttons, making existing treatments work better and offering a fresh option for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10982470 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat Diffuse Large B-Cell Lymphoma (DLBCL) by utilizing specially designed molecules that can manipulate cancer cell behavior. The study focuses on rewiring the cancer cell's internal mechanisms to activate genes that promote cell death, effectively causing the cancer cells to self-destruct. By targeting specific proteins that are overactive in DLBCL, the researchers aim to enhance the effectiveness of existing treatments and provide a new therapeutic option for patients. The methodology involves creating bifunctional molecules that can bind to cancer drivers and proapoptotic gene promoters, leading to a significant reduction in cancer cell survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Diffuse Large B-Cell Lymphoma who have not responded adequately to standard therapies.
Not a fit: Patients with other types of lymphoma or those who have already achieved remission may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with DLBCL, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using similar approaches to target cancer cell mechanisms, indicating potential for success in this novel application.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Crabtree, Gerald R. — Stanford University
- Study coordinator: Crabtree, Gerald R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.